Evaluation of Puromycin-Induced Podocyte Injury and Protective Effects of Voclosporin Using Induced Pluripotent Stem Cells from a Patient with Nephrotic Syndrome Harboring an INF2 Variant. (PubMed, Stem Cells Dev) - Jun 19, 2026 - "Cyclosporine A (CsA) or voclosporin (VCS) was administered as a 1-h pretreatment before PAN exposure to evaluate their podocyte-protective effects. In conclusion, we established a patient-specific kidney organoid model of INF2-associated FSGS that reliably recapitulated podocyte vulnerability to toxic injury. This platform demonstrated that calcineurin inhibitors, including the novel agent VCS, exert direct podocyte-protective effects in a genetic FSGS background and provide a practical system for mechanistic studies and therapeutic screening."
Journal • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease • PODXL
|
|
Akihisa Kato; Akihito Tanaka; Asuka Horinouchi; Chikao Onogi; Eri Koshi-Ito; Hangsoo Kim; Jun Matsumoto; Kayaho Maeda; Kazuhiro Furuhashi; Keita Hattori; Kumiko Fujieda; Noritoshi Kato; Saki Sakamoto; Shoichi Maruyama; Tomohiro Kawazoe; Yu Watanabe
|